Context Therapeutics Inc announced that it has ended its first quarter of 2022 with $45.7 million in cash and equivalents as of March 31, which the company.
Context Therapeutics Inc announced that it has ended its first quarter of 2022 with $45.7 million in cash and equivalents as of March 31, which the company.